TABLE 1.

Characteristics of HIV-1-infected patients receiving HAART

Patient and sample	Time (days)a of:			No. of CD4+ cells/mm3	No. of HIV-1 RNA copies/ml of plasmab
	Sampling	HAART initiation	Seroconversion
1		90	62
I	64			452	38,900
II	729			860	<50 (20)
III	954			986	<50 (12)
IV	1,458			1,002	<50 (31)
2		121	41
I	41			702	492,000
II	1,051			842	<50 (20)
III	1,235			815	<50 (8)
IV	1,751			788	<50 (7)
3		79	58
I	78			777	22,200
II	425			1,423	<50 (25)
III	739			1,518	<50 (14)
IV	1,153			1,265	<50 (6)
4		20	30
I	10			381	3,500,000
II	423			928	<50 (30)
III	1,251			841	<50 (12)
5		18	18
I	18			755	6,000,000
II	578			1,061	<50 (14)
III	941			1,001	<50 (17)
6		80	60
I	35			435	67,862
II	820			718	<50 (18)
III	1,017			848	<50 (10)
IV	1,202			803	<50 (11)
7		21	20
I	20			680	12,500
II	485			729	<50 (4)
III	725			801	<50 (4)
IV	1,205			832	<50 (5)

^aDays after the onset of acute syndrome of HIV infection (3, 44).

^bLevels of plasma viral RNA were measured by a commercial RT-PCR assay (Amplicor ultrasensitive HIV-1 monitor assay; Roche) (3, 44). Numbers in parentheses are levels of virion RNA determined by a sensitive limiting-dilution RT-PCR (see Materials and Methods).